Payment overview · 2025
General Payments
$461.83
19 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Hwang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BROOMALL, PA · NPI 1912249061
Verified facts
What the public records show
CMS Open Payments records show Christopher Hwang, M.D. received $461.83 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.01 | 14.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.91 | 11.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.63 | 10.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.92 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.72 | 9.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.48 | 7.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.97 | 6.9% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $28.01 | 6.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.03 | 5.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.00 | 5.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.59 | 4.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.52 | 4.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.04 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.83 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.91 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 191 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 48 |
| Lisinopril | Lisinopril | 165 | 48 |
| Gabapentin | Gabapentin | 135 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 36 |
| Eliquis | Apixaban | 121 | 24 |
| Metformin Hcl | Metformin Hcl | 121 | 35 |
| Sertraline Hcl | Sertraline Hcl | 120 | 28 |
| Losartan Potassium | Losartan Potassium | 114 | 36 |
| Furosemide | Furosemide | 110 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 38 |
| Trazodone Hcl | Trazodone Hcl | 98 | 37 |
| Carvedilol | Carvedilol | 95 | 24 |
| Omeprazole | Omeprazole | 85 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 22 |
| Donepezil Hcl | Donepezil Hcl | 80 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 22 |
| Famotidine | Famotidine | 70 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 20 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 20 |
| Mirtazapine | Mirtazapine | 59 | 21 |
| Levetiracetam | Levetiracetam | 58 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 21 |
| Lorazepam | Lorazepam | 56 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 15 |
| Simvastatin | Simvastatin | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 15 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 44 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 11 |
| Allopurinol | Allopurinol | 42 | 12 |
| Baclofen | Baclofen | 41 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Prednisone | Prednisone | 33 | 20 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | 11 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Budesonide | Budesonide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Desonide | Desonide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.83 · 19 records | ABBVIE INC. | ABRYSVO, AREXVY, CAMZYOS, COMIRNATY, Dexcom G6 Transmitter, EVENITY, INGREZZA, INSPIRE, LEQVIO, MOUNJARO, Nayzilam, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, VYNDAMAX, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error